Similar articles

• A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.

  Hanto DW, Jendrisak MD, McCullough CS, So SK, Marsh JW, Rush T, Michalski S, Phelan D, Mohanakumar T. Hanto DW, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1050-1. Transplant Proc. 1991. PMID: 1899150 Clinical Trial. No abstract available.
• MALG vs OKT3 following renal transplantation: a randomized prospective trial.

  Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DE, Najarian JS. Frey DJ, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1048-9. Transplant Proc. 1991. PMID: 1899149 Clinical Trial. No abstract available.
• Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.

  De Pauw L, Abramowicz D, Goldman M, Vereerstraeten P, Kinnaert P, Toussaint C. De Pauw L, et al. Transplant Proc. 1990 Aug;22(4):1759-60. Transplant Proc. 1990. PMID: 2117800 Clinical Trial. No abstract available.
• Clinical development of Orthoclone OKT3.

  Cosimi AB. Cosimi AB. Transplant Proc. 1987 Apr;19(2 Suppl 1):7-16. Transplant Proc. 1987. PMID: 3105142 Review. No abstract available.
• Monoclonal antibody OKT3 in cardiac and renal transplantation.

  Norman DJ. Norman DJ. Bibl Cardiol. 1988;(43):27-32. Bibl Cardiol. 1988. PMID: 3147656 Review. No abstract available.